MedWatch

Orphazyme obtains special status in the US

The US Food and Drug Agency (FDA) has granted the so-called Orphan Drug Designation to Orphazyme’s main candidate in one of the indications, in which the drug is currently being tested.

Foto: Orphazyme

Just before the forthcoming IPO, the biotech company Orphazyme receives solid regulatory support from the FDA that has granted Orphan Drug Designation to the Danish company’s candidate drug arimoclomol.

This is according to a stock market release from the company.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier